{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:36:11Z","timestamp":1774064171704,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00393-022-01226-0","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T16:09:48Z","timestamp":1654618188000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is tapering or discontinuation of biologic treatment in patients with radiographic and nonradiographic axial spondyloarthritis reasonable?","Ist das Ausschleichen oder Absetzen einer Therapie mit Biologika bei Patienten mit radiologischer und nichtradiologischer Spondylarthritis sinnvoll?"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4178-8730","authenticated-orcid":false,"given":"Halil","family":"Harman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedim","family":"Kaban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"1226_CR1","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.berh.2014.10.007","volume":"28","author":"N Garg","year":"2014","unstructured":"Garg\u00a0N, van den Bosch\u00a0F, Deodhar\u00a0A (2014) The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol 28:663\u2013672","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"1226_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit\u00a0M, van der Heijde\u00a0D, Landew\u00e9\u00a0R et\u00a0al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783","journal-title":"Ann Rheum Dis"},{"key":"1226_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2018.1477591","volume":"14","author":"M Protopopov","year":"2018","unstructured":"Protopopov\u00a0M, Poddubnyy\u00a0D (2018) Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol 14:525\u2013533","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1226_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden\u00a0S, Valkenburg\u00a0HA, Cats\u00a0A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"key":"1226_CR5","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde\u00a0D, Ramiro\u00a0S, Landewe\u00a0R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991","journal-title":"Ann Rheum Dis"},{"key":"1226_CR6","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward\u00a0MM, Deodhar\u00a0A, Gensler\u00a0LS et\u00a0al (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71:1599\u20131613","journal-title":"Arthritis Rheumatol"},{"key":"1226_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010952.pub2","author":"FP Kroon","year":"2015","unstructured":"Kroon\u00a0FP, van der Burg\u00a0LR, Ramiro\u00a0S et al (2015) Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010952.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1226_CR8","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward\u00a0MM, Deodhar\u00a0A, Akl\u00a0EA et\u00a0al (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 68:282\u2013298","journal-title":"Arthritis Rheumatol"},{"key":"1226_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-019-1885-z","volume":"21","author":"DE Furst","year":"2019","unstructured":"Furst\u00a0DE, Louie\u00a0JS (2019) Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther 21:135","journal-title":"Arthritis Res Ther"},{"key":"1226_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle\u00a0DG, McInnes\u00a0IB, Kirkham\u00a0BW et al (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 78:1167\u20131178","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1226_CR11","doi-asserted-by":"publisher","first-page":"R94","DOI":"10.1186\/ar3369","volume":"13","author":"S Arends","year":"2011","unstructured":"Arends\u00a0S, Brouwer\u00a0E, van der Veer\u00a0E et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a\u00a0prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"1226_CR12","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/rheumatology\/ker281","volume":"50","author":"N Busquets","year":"2011","unstructured":"Busquets\u00a0N, Tomero\u00a0E, Descalzo\u00a0M\u00c1 et\u00a0al (2011) BIOBADASER 2.0 Study Group. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology 50(11):1999\u20132004","journal-title":"Rheumatology"},{"key":"1226_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/1824794","volume":"2017","author":"AN Malaviya","year":"2017","unstructured":"Malaviya\u00a0AN, Rawat\u00a0R, Agrawal\u00a0N et\u00a0al (2017) The Nonradiographic axial spondyloarthritis, the radiographic axial spondyloarthritis, and ankylosing spondylitis: the Tangled Skein of rheumatology. Int J Rheumatol 2017:1\u20139","journal-title":"Int J Rheumatol"},{"issue":"12","key":"1226_CR14","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett\u00a0S, Jenkinson\u00a0T, Kennedy\u00a0LG et\u00a0al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J\u00a0Rheumatol 21(12):2286\u20132291","journal-title":"J Rheumatol"},{"issue":"12","key":"1226_CR15","first-page":"1694","volume":"21","author":"TR Jenkinson","year":"1994","unstructured":"Jenkinson\u00a0TR, Mallorie\u00a0PA, Whitelock\u00a0HC et\u00a0al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J\u00a0Rheumatol 21(12):1694\u20131698","journal-title":"J Rheumatol"},{"issue":"3","key":"1226_CR16","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos\u00a0X, Listing\u00a0J, Brandt\u00a0J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3\u00a0years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439\u2013R444","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"1226_CR17","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen\u00a0X, Zhang\u00a0T, Wang\u00a0W et\u00a0al (2018) Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin Rheumatol 37(6):1625\u20131632","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1226_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40744-018-0129-z","volume":"5","author":"PJ Mease","year":"2018","unstructured":"Mease\u00a0PJ, van der Heijde\u00a0D, Karki\u00a0C et al (2018) Tumor necrosis factor inhibitor discontinuation in patients with ankylosing spondylitis: an observational study from the US-based Corrona registry. Rheumatol Ther 5(2):537\u2013550","journal-title":"Rheumatol Ther"},{"issue":"8","key":"1226_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3899\/jrheum.160363","volume":"43","author":"E Lubrano","year":"2016","unstructured":"Lubrano\u00a0E, Perrotta\u00a0MF, Manara\u00a0M et\u00a0al (2016) Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: a retrospective study. J\u00a0Rheumatol 43(8):1541\u20131546. https:\/\/doi.org\/10.3899\/jrheum.160363 (Erratum in: J Rheumatol. 2016 Sep;43(9):1772)","journal-title":"J Rheumatol"},{"key":"1226_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab741","author":"CAJ Michielsens","year":"2021","unstructured":"Michielsens\u00a0CAJ, den Broeder\u00a0N, Mulder\u00a0MLM et\u00a0al (2021) Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a\u00a0retrospective cohort study. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab741","journal-title":"Rheumatology"},{"key":"1226_CR21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab755","author":"M Wetterslev","year":"2021","unstructured":"Wetterslev\u00a0M, Georgiadis\u00a0S, Juul S\u00f8rensen\u00a0I et al (2021) Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab755","journal-title":"Rheumatology"},{"key":"1226_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun\u00a0J, Baraliakos\u00a0X, Deodhar\u00a0A et al (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4\u2011year results from the MEASURE 1\u00a0study. Rheumatology 58:859\u2013868","journal-title":"Rheumatology"},{"key":"1226_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X211041854","volume":"13","author":"J Braun","year":"2021","unstructured":"Braun\u00a0J, Kiltz\u00a0U, B\u00fchring\u00a0B et\u00a0al (2021) Secukinumab in axial spondyloarthritis: a\u00a0narrative review of clinical evidence. Ther Adv Musculoskel Dis 13:1\u201318","journal-title":"Ther Adv Musculoskel Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-022-01226-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-022-01226-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:04:20Z","timestamp":1708416260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-022-01226-0"}},"subtitle":["A\u00a0local cohort study","Eine lokale Kohortenstudie"],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":23,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1226"],"URL":"https:\/\/doi.org\/10.1007\/s00393-022-01226-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"11 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"H.\u00a0Harman and N.\u00a0Kaban declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors. All studies mentioned were in accordance with the ethical standards indicated in each case.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}